NHS England
NHS England is dedicated to improving health outcomes for individuals in England by placing patients and the public at the center of its operations. The organization aims to be open, evidence-based, and inclusive, ensuring transparency in decision-making and operations. By encouraging public participation and treating individuals with respect, NHS England seeks to develop insights that enhance health outcomes while ensuring that no community is overlooked. The organization supports clinical leaders through clinical commissioning groups and various networks, empowering them to make informed decisions and use taxpayer funds effectively to provide high-quality services. Engaging staff is equally prioritized, as they are viewed as essential to the organization's success. Grounded in the values of the NHS Constitution, NHS England fosters a culture of sharing knowledge and learning from experiences. Through collaboration and partnerships, NHS England strives to deliver exemplary patient services, aiming not only for excellence within the country but also aspiring to set a global standard.
Top Stages
15 past transactions
Artificial Intelligence Centre for Value Based Healthcare
Grant in 2024
The AI Center created advanced AI algorithms using NHS medical pictures and patient data to give physicians tools to expedite and enhance diagnosis and care across many patient paths.
Cyted Health
Grant in 2023
Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.
Ibex Medical Analytics
Grant in 2023
Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.
Medtronic
Grant in 2023
Medtronic is a global leader in healthcare technology, specializing in innovative solutions for complex medical conditions. The company offers a wide range of treatments and therapies, including patient monitoring systems, robotic surgery, insulin pumps, and cardiac devices, catering to various health areas such as lungs, brain, diabetes, heart, and orthopedics. Medtronic's extensive portfolio addresses 70 different medical conditions, aiming to improve and extend the lives of patients worldwide.
Mendelian
Grant in 2023
Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. It employs advanced machine learning and knowledge reasoning techniques to analyze patients' clinical features, allowing physicians to identify the genes and mutations responsible for various undiagnosed conditions. By utilizing an intelligent agent, Mendelian streamlines the process of matching patients' phenotypic characteristics with potential genetic causes, thereby enhancing the ability of healthcare professionals to diagnose rare diseases more efficiently. This innovative approach aims to improve patient outcomes by enabling earlier detection and treatment of these complex conditions.
Tommy’s
Grant in 2023
Tommy's is a charity that carries out research into the causes of miscarriage, stillbirth, and premature birth. They support them throughout their entire pregnancy journey from conception to postpartum recovery. Their free digital tools, calculators, and resources will help them have a healthy and happy pregnancy. All the information and support they need, including tools and news, and stories covering the entire pregnancy.
Oxford Cancer Biomarkers
Grant in 2023
Oxford Cancer Biomarkers is a company focused on the development and commercialization of a range of biomarker tests specifically for colorectal cancer, aimed at enhancing personalized medicine in oncology. Closely associated with the Institute of Cancer Medicine at Oxford University, where its founders conduct leading research in translational cancer science, the company has established partnerships with pharmaceutical firms to leverage its discovery platforms, CancerNav and ToxNav, in creating companion diagnostic tests for emerging drugs. The tests provided by Oxford Cancer Biomarkers assess dihydropyridine dehydrogenase deficiency, identify variants linked to partial dihydropyrimidine deficiency, and evaluate the risk of potential toxicity, allowing healthcare providers to analyze resected tissue samples and predict relapse risk for patients more effectively.
icometrix
Grant in 2023
Icometrix specializes in enhancing patient care through AI-driven imaging analysis. Founded in 2011 as a spin-off from Belgian universities, it offers standardized measurements on brain MRI scans for neurological disorder patients. Its flagship product, MSmetrix, detects lesions and measures volumes, with EU market approval and pending FDA clearance. Icometrix also supports clinical trials and research studies, processing large batches of imaging data.
Royal United Hospital
Grant in 2023
Royal United Hospital Bath NHS Foundation Trust provides acute treatment and cares for people in Bath and the surrounding towns.
Cibiltech
Grant in 2023
Cibiltech is a company that specializes in developing digital solutions aimed at enhancing predictive medicine, particularly in the field of renal transplantation. Its innovative algorithm assists nephrologists in assessing the individual risk of graft loss for kidney transplant patients, facilitating tailored treatment plans. By providing personalized prognoses and enabling risk stratification, Cibiltech's software improves the capability for remote patient monitoring and integrates smoothly into clinical workflows. This approach not only promotes longer graft survival and extends patient lifespans but also optimizes the management of clinical resources, ultimately leading to improved medical outcomes and decision-making for healthcare professionals.
InSightec
Corporate Round in 2020
InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.
Optos
Grant in 2020
Optos plc is a manufacturer of advanced retinal imaging devices aimed at enhancing patient care in the eyecare sector. The company specializes in ultra-widefield, high-resolution digital imaging, producing optomaps that capture approximately 82% of the retina in a single image, a capability unmatched by other devices. Optos offers a diverse range of imaging products tailored for various customer segments and patient needs. The P200 and 200Dx devices are designed for wellness screening by optometrists and ophthalmologists in primary care, while the P200C devices cater to the more demanding clinical imaging requirements in secondary care and those managing advanced ocular diseases. Additionally, the P200MA and 200Tx devices support ophthalmologists and retinal specialists in delivering medical care. By providing these innovative tools, Optos enables eyecare professionals to discover, diagnose, document, and treat ocular pathologies that may otherwise go unnoticed with traditional examination techniques.
Inovus Medical
Grant in 2019
Inovus Medical is a company that specializes in designing and manufacturing medical simulation products, primarily aimed at enhancing surgical training. Founded in 2012 and based in Saint Helens, United Kingdom, Inovus produces a range of simulators, including take-home and institutional laparoscopic simulators, which facilitate the training of surgical trainees and residents. Their products cover essential procedures such as laparoscopic appendectomy and cholecystectomy, as well as training tools for critical care and general medicine. By providing accessible and versatile healthcare training equipment, Inovus Medical aims to improve surgical skills and, consequently, the quality of patient care. The company serves its customers through online platforms, making its training solutions widely available.
Corporation Pop
Grant in 2016
Corporation Pop designs original and engaging interactive tools that help their clients communicate with their audience.
Founded in 2007, the company is headquartered in Manchester, Manchester, United Kingdom.
Blue Maestro
Non Equity Assistance in 2014
Blue Maestro is a leading designer and developer of connected products and solutions, from consumer devices through to their work with NHS England on the next generation of medicine adherence sensors. They have a number of innovative products and solutions under development, several that are patent pending. Meet some of Blue Maestro’s management team below.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.